China's rapid rise creates 'heightened risks' for pharma: PwC
PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP security, regulatory compliance and strategic alignment.”

Jun 17, 2025 0
Jun 17, 2025 0
Jun 17, 2025 0
Jun 17, 2025 0
Jun 16, 2025 0
Jun 16, 2025 0
Jun 15, 2025 0
Jun 15, 2025 0
Jun 15, 2025 0
Jun 18, 2025 0
Jun 17, 2025 0
Jun 16, 2025 0
Jun 16, 2025 0
Jun 13, 2025 0
Jun 13, 2025 0
Jun 13, 2025 0
Jun 13, 2025 0
Jun 18, 2025 0
Jun 17, 2025 0
Or register with email
May 12, 2025 0
May 15, 2025 0
May 12, 2025 0
May 12, 2025 0
May 14, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.